Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
|Articles|February 1, 2002
Supplements and Featured Publications
- New Approaches to the Treatment of Migraine: Clinical and Economic Impact
- Volume 8
- Issue 3 Suppl
Participating Faculty
Advertisement
Articles in this issue
almost 25 years ago
Introductionalmost 25 years ago
Migraine: Diagnosis, Management, and New Treatment Optionsalmost 25 years ago
Almotriptan: A Review of Pharmacology, Clinical Efficacy, and TolerabilityAdvertisement
Related to this article
In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.
Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.
Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Advertisement
Advertisement
Trending on AJMC
1
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
2
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
3
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
4
HS Comorbidities: Navigating Metabolic, Bowel, Cardiovascular, and Mental Health Risks
5